Dr. Igor Medic, M.D.
Hematology & Oncology (Hematology & Oncology Physician)
5555 Grossmont Center Dr
La Mesa, CA 91942
Who else practices at this address →
San Diego County includes primary care (1% of residents) and mental health (1% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 21
- In the NPI registry since
- 2011
- Medicare patients seen, 2024
- 500
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2011Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
CA license 146970
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Sharp Memorial Hospital San Diego, CA
- Grossmont Hospital La Mesa, CA
- Sharp Chula Vista Medical Center Chula Vista, CA
- Sharp Coronado Hospital and Hlthcr Ctr Coronado, CA
Medical groups
- Cancer Center Oncology Medical Group Inc - East County (4 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 500
- Services billed
- 251,351
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Injection, ferric carboxymaltose, 1 mg | 58,500 | 36 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 40,100 | 21 |
| Injection, pembrolizumab, 1 mg | 20,000 | 23 |
| Injection, dexamethasone sodium phosphate, 1 mg | 3,855 | 38 |
| Injection, palonosetron hcl, 25 mcg | 2,560 | 36 |
| Injection, leucovorin calcium, per 50 mg | 1,604 | 13 |
| Injection, fluorouracil, 500 mg | 1,032 | 13 |
| Established patient office or other outpatient visit, 30-39 minutes | 929 | 335 |
| Injection of additional new drug or substance into vein | 626 | 45 |
| Administration of chemotherapy into vein, 1 hour or less | 452 | 68 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Anastrozole Other prescribers in La Mesa, CA | 157 |
| Xtandi (enzalutamide) | 87 |
| Levothyroxine Sodium Other prescribers in La Mesa, CA | 83 |
| Dexamethasone Other prescribers in La Mesa, CA | 73 |
| Oxycodone Hcl Other prescribers in La Mesa, CA | 73 |
| Revlimid (lenalidomide) | 71 |
| Ondansetron Hcl Other prescribers in La Mesa, CA | 63 |
| Exemestane | 55 |
| Tamoxifen Citrate Other prescribers in La Mesa, CA | 54 |
| Acyclovir Other prescribers in La Mesa, CA | 50 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 47 companies reported 130 payments worth $3,052 in total to this clinician.
| Novartis Pharmaceuticals Corporation | $252 |
|---|---|
| Celgene Corporation | $234 |
| Pfizer Inc. | $209 |
| GlaxoSmithKline, LLC. | $149 |
| Genentech USA, Inc. | $128 |
| AstraZeneca Pharmaceuticals LP | $124 |
| Genzyme Corporation | $116 |
| Merck Sharp & Dohme LLC | $115 |
| Food and Beverage | $3,032 |
|---|---|
| Education | $20.00 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Aveo Pharmaceuticals, Inc. Jan 6, 2025 | Education FOTIVDA · Oncology · in-kind | $20.00 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $75,331 in research payments for these studies, mostly to the institutions running them.
- Project Pragmatica# A Randomized Phase III Study of Pembrolizumab and Ramucirumab versus standard of care SOC for Participants Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer
Merck Sharp & Dohme LLC - A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors
Incyte Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.